Clinical trials are investigating NCS for cancer treatment, and one trial demonstrated its ability to reduce albuminuria in patients with diabetic nephropathy when combined with angiotensin-converting enzyme inhibitors [42]. This evidence concerns the gene ACE and diabetic kidney disease.